William Blair Maintains UniQure NV(QURE.US) With Buy Rating
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating
UNIQURE Earnings Results: $QURE Reports Quarterly Earnings
uniQure NV | 10-Q: Quarterly report
UniQure Reports Breakthrough Therapy Designation for AMT-130 and Financial Results for Q1 2025
uniQure NV | 8-K: uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
UniQure: Cash, Cash Equivalents and Current Investment Securities of $409M as of March 31 Expected to Fund Ops Into 2H of 2027 >QURE
Press Release: UniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
UniQure 1Q Rev $1.57M >QURE
UniQure 1Q Loss/Shr 82c >QURE
Earnings Scheduled For May 9, 2025
UNIQURE Earnings Preview: Recent $QURE Insider Trading, Hedge Fund Activity, and More
UniQure Down Nearly 27%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk
UniQure Is Maintained at Buy by Chardan Capital
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 09
UniQure to Announce First Quarter 2025 Financial Results
Fed Policy Shifts Could Trigger a Move to Small Caps – Morgan Stanley
Leerink Partners Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $48
Express News | Uniqure NV : Leerink Partners Raises Target Price to $48 From $44
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70